Kanter K R, Tam V K, Vincent R N, Cuadrado A R, Raviele A A, Berg A M
Department of Surgery, Emory University School of Medicine, Atlanta, Georgia 30322, USA.
Ann Thorac Surg. 1999 Aug;68(2):527-30; discussion 530-1. doi: 10.1016/s0003-4975(99)00616-5.
Cardiac transplantation is an accepted treatment for children with end-stage heart failure or complex or inoperable congenital defects.
Since 1988, 95 transplants have been performed in 89 children aged 4 days to 18 years (median 6.9 years, 42 patients 0-5 years). Fifty-eight (61%) had congenital or acquired heart disease, 31 (33%) had idiopathic cardiomyopathy, and 6 (6%) were retransplants. Fifty-seven of the patients had prior cardiac surgery with a range of one to eight procedures (mean 3.4 procedures/patient). At the time of transplantation, 53 (56%) were United Network for Organ Sharing (UNOS) status I, including 23 children on mechanical ventilation and 4 with mechanical circulatory support.
Thirty-day survival in this group was 96%. Posttransplant results showed a median time of ventilation of 1 day (mean 3.0+/-5.7 days), median duration of inotropic support of 2 days (mean 2.7+/-2.3 days), median intensive care unit (ICU) stay of 4 days (mean 6.9+/-9.6 days), and median hospitalization of 9 days (mean 14.3+/-13.9 days). Follow-up from 1 month to 10.3 years (mean 3.1 years) has demonstrated a 1-year actuarial survival of 79% and a 5-year actuarial survival of 69%. Rejection, both acute and chronic, accounted for the vast majority of deaths.
Pediatric heart transplantation can be accomplished with excellent early survival despite multiple prior cardiac operations and relative severity of illness. Parameters such as postoperative ventilation, inotropic support, ICU stay, and hospitalization can be kept at reasonable levels with acceptable long-term results, although rejection remains a serious problem.
心脏移植是终末期心力衰竭或复杂或无法手术的先天性缺陷儿童可接受的治疗方法。
自1988年以来,已对89名年龄在4天至18岁(中位年龄6.9岁,42例患者年龄在0至5岁)的儿童进行了95例移植手术。58例(61%)患有先天性或后天性心脏病,31例(33%)患有特发性心肌病,6例(6%)为再次移植。57例患者曾接受过心脏手术,手术次数从1次到8次不等(平均每位患者3.4次手术)。在移植时,53例(56%)为器官共享联合网络(UNOS)I级状态,其中包括23名接受机械通气的儿童和4名接受机械循环支持的儿童。
该组患者30天生存率为96%。移植后结果显示,中位通气时间为1天(平均3.0±5.7天),中位血管活性药物支持时间为2天(平均2.7±2.3天),中位重症监护病房(ICU)住院时间为4天(平均6.9±9.6天),中位住院时间为9天(平均14.3±13.9天)。随访时间从1个月至10.3年(平均3.1年),1年实际生存率为79%,5年实际生存率为69%。急性和慢性排斥反应是绝大多数死亡的原因。
尽管此前多次进行心脏手术且病情相对严重,但小儿心脏移植仍可实现出色的早期生存率。术后通气、血管活性药物支持、ICU住院时间和住院时间等参数可维持在合理水平,并取得可接受的长期效果,不过排斥反应仍然是一个严重问题。